# IL-1ra Dose-range Study for Moderate-to-severe TBI Patients

> **NCT02997371** · PHASE2 · UNKNOWN · sponsor: **Adel Helmy** · enrollment: 60 (estimated)

## Conditions studied

- Traumatic Brain INjury

## Interventions

- **DRUG:** Anakinra Prefilled Syringe
- **DRUG:** Isotonic saline

## Key facts

- **NCT ID:** NCT02997371
- **Lead sponsor:** Adel Helmy
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-10
- **Primary completion:** 2021-10
- **Final completion:** 2021-10
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2017-05-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02997371

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02997371, "IL-1ra Dose-range Study for Moderate-to-severe TBI Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02997371. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*